Back to search results

Study of Trifluridine/Tipiracil + Oxaliplatin for Advanced Biliary Tract Cancer

This study is for people with advanced or metastatic biliary tract cancer (cancer that has spread) who have already received one treatment that didn't work or stopped working. Researchers are testing a combination of two drugs: trifluridine/tipiracil (pills taken by mouth) and oxaliplatin (given by IV). Oxaliplatin has been used for biliary tract cancer before, but trifluridine/tipiracil is new for this type of cancer. The goal is to see if this combination works better than current treatments to control the cancer. They will measure how well the cancer is controlled every 8 weeks for up to 6 months. About 27 people are expected to join this study.

Study design
This is an interventional study, meaning participants will receive a specific treatment. It plans to enroll 27 participants.
What's involved
You would take trifluridine/tipiracil pills daily for 5 days, and receive oxaliplatin by IV on day 1, every 14 days. Your disease control will be checked every 8 weeks for up to 6 months.
Compensation
Not stated in the trial record.
Follow-up
Your disease control will be measured every 8 weeks until treatment stops, for up to 6 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07146646

Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer

Recruiting
PHASE2Ages 19+InterventionalTreatment
Case Comprehensive Cancer Center
~27 participants
Updated 2026-02-19 on ClinicalTrials.gov
What's tested:Trifluridine/tipiracilOxaliplatin

At a glance

Recruiting sites
1 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Disease control rate (DCR) by RECIST v1.1
Measured over Every 8 weeks until treatment discontinuation, up to 6 months

Conditions

Biliary Tract Cancer
Biliary Tract Neoplasms
Cholangiocarcinoma
Gallbladder Cancer
Gallbladder Carcinoma

Explore related trials

CholangiocarcinomaGallbladder CarcinomaMalignant neoplasm of biliary tract

Where it's being run

2 sites across 1 states
Ohio2

Study leadership

  • Madison Conces, MD · PRINCIPAL_INVESTIGATOR · Case Comprehensive Cancer Center, University Hospitals

Who to contact

Madison Conces, MD
[email protected]
216-844-3951
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Participants must have histologically or cytologically confirmed biliary tract cancer (BTC) including cholangiocarcinoma and gallbladder carcinoma. Individuals with ampullary cancers will not be considered eligible. Cancer must be advanced stage or metastatic.
Participants must have received only one line of systemic therapy for advanced or metastatic BTCs.
Note: Individuals who have either progressed or are intolerant to the prior therapy can be included in this study.
Age \>18 years on day of signing informed consent. Because no dosing or adverse event data are currently available on the use of FTD/TPI in individuals ≤18 years of age, children are excluded from this study.
Performance status: ECOG performance status of 0 or 1.
At least one index lesion is measurable based on RECIST 1.1.
Participants must have organ and marrow function as defined below:
Absolute neutrophil count ≥ 1,500/mcL
Platelet count ≥75,000/mcL
AST (SGOT) ≤ 2.5 X institutional upper limit of normal or ≤ 5 × ULN for participants with liver metastases
ALT (SGPT) ≤ 2.5 X institutional upper limit of normal or ≤ 5 × ULN for participants with liver metastases
Total bilirubin ≤ 1.5 × ULN or direct bilirubin ≤ ULN for participants with bilirubin levels \>1.5 x ULN
Serum Creatinine ≤ 1.5 x upper limit of normal (ULN) or creatinine clearance ≥60 mL/min for participants with creatinine levels \>1.5 x ULN (Cockcroft-Gault method)
Participants must have recovered adequately from any major surgery, prior to starting therapy.
Participants must have the ability to understand and the willingness to sign a written informed consent document.
Agree to use adequate method of contraception.

Exclusion

Participants receiving any other investigational agents.
Participant has received investigational therapy within 4 weeks or within 5 half-lives of the therapeutic agent (whichever is shorter).
Received more than one line of systemic therapy for bile duct cancer. Adjuvant therapy will not be counted as line of systemic therapy.
Receiving systemic steroid therapy (\>10mg prednisone or equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment.
Prior treatment with FTD/TPI or oxaliplatin.
Known additional malignancy that currently requires active treatment. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has already undergone potentially curative therapy.
Known central nervous system metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are stable without evidence of new or enlarging brain metastases and are not using steroids for at least 7 days prior to trial treatment.
Active autoimmune disease requiring systemic treatment within the past 3 months or a documented history of clinically severe autoimmune disease, or a syndrome that requires systemic steroids (\> 10 mg/day or equivalent of prednisone) or immunosuppressive agents. (thyroid disease and diabetes are allowed)
Interstitial lung disease or active, non-infectious pneumonitis.
Active infection requiring systemic antibiotics.
History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the individual's participation for the full duration of the trial, or is not in the best interest of the individual to participate, in the opinion of the treating investigator.
Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial, in the opinion of the treating investigator.
Participants with uncontrolled intercurrent illness including, but not limited to symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations/substance abuse disorders that would limit compliance with study requirements.
Participants pregnant or breastfeeding expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 5 months after the last dose of trial treatment. Pregnant or breastfeeding women are excluded from this study because it is unknown if the combination of FTD/TPI and oxaliplatin create the potential for teratogenic or abortifacient effects. Because there is an unknown, but potential risk for adverse events in nursing infants secondary to treatment of the mother with the study drug combination, breastfeeding should be discontinued if the mother is enrolled on this trial.

What this trial measures

  • Disease control rate (DCR) by RECIST v1.1Every 8 weeks until treatment discontinuation, up to 6 months

    DCR is the percentage of participants whose cancer did not get worse after treatment (i.e. the percentage of participants who had CR, PR, or SD, as defined below), and this will be measured by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria. Per RECIST v1.1, Complete Response (CR) is defined as disappearance of all target lesions. Partial Response (PR) is defined as a 30% decrease in the sum of diameters of target lesions. Progressive Disease (PD) is defined as a 20% increase in the sum of diameters of target lesions with an absolute increase of at least 5 millimeters (mm) or the appearance of one or more new lesions. Stable Disease (SD) is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.